Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period 
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. 
Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3. 
Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations 
History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases. 
History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. 
History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease. 
Acute disease at the time of enrolment 
Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical 
A family history of congenital or hereditary immunodeficiency. 
Major congenital defects or serious chronic illness. 
Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study.       
    

NCT00344318_exc_T1
Drug
product any investigational other than the study vaccine(s)
NCT00344318_exc_T2
Drug
non-registered product any other than the study vaccine(s)
NCT00344318_exc_T3
Drug
drug
NCT00344318_exc_T4
Drug
vaccine
NCT00344318_exc_T5
Scope
drug or vaccine
NCT00344318_exc_T6
Scope
any investigational or non-registered product other than the study vaccine(s)
NCT00344318_exc_T7
Temporal
within 30 days
NCT00344318_exc_T8
Observation
planned use
NCT00344318_exc_T9
Temporal
during the study period
NCT00344318_exc_T10
Drug
immunosuppressants
NCT00344318_exc_T11
Drug
other immune-modifying drugs
NCT00344318_exc_T12
Temporal
within six months
NCT00344318_exc_T13
Temporal
Chronic
NCT00344318_exc_T14
Temporal
more than 14 days
NCT00344318_exc_T15
Scope
immunosuppressants or other immune-modifying drugs
NCT00344318_exc_T16
Observation
Planned
NCT00344318_exc_T17
Drug
vaccine
NCT00344318_exc_T18
Qualifier
not foreseen by the study protocol
NCT00344318_exc_T19
Temporal
period starting one month before each dose of vaccine(s)
NCT00344318_exc_T20
Temporal
1 month after dose 3
NCT00344318_exc_T21
Temporal
ending 7 days after dose 1 and dose 2
NCT00344318_exc_T22
Drug
dose 1
NCT00344318_exc_T23
Drug
dose 2
NCT00344318_exc_T24
Drug
dose 3
NCT00344318_exc_T25
Scope
dose 1 and dose 2
NCT00344318_exc_T26
Scope
period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3
NCT00344318_exc_T27
Drug
vaccination
NCT00344318_exc_T28
Condition
diphtheria
NCT00344318_exc_T29
Condition
tetanus
NCT00344318_exc_T30
Condition
pertussis
NCT00344318_exc_T31
Condition
polio
NCT00344318_exc_T32
Condition
hepatitis B
NCT00344318_exc_T33
Condition
Haemophilus influenzae type b
NCT00344318_exc_T34
Condition
S. pneumoniae
NCT00344318_exc_T35
Temporal
within the first two weeks of life
NCT00344318_exc_T36
Qualifier
first dose can be given
NCT00344318_exc_T37
Scope
diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae
NCT00344318_exc_T38
Scope
vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae
NCT00344318_exc_T39
Drug
vaccines
NCT00344318_exc_T40
Observation
History
NCT00344318_exc_T41
Condition
diphtheria
NCT00344318_exc_T42
Condition
tetanus
NCT00344318_exc_T43
Condition
pertussis
NCT00344318_exc_T44
Condition
hepatitis B
NCT00344318_exc_T45
Condition
polio
NCT00344318_exc_T46
Condition
Haemophilus influenzae type b
NCT00344318_exc_T47
Scope
diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b
NCT00344318_exc_T48
Condition
allergic disease
NCT00344318_exc_T49
Observation
History
NCT00344318_exc_T50
Condition
reactions allergic
NCT00344318_exc_T51
Scope
allergic disease or reactions
NCT00344318_exc_T52
Qualifier
exacerbated
NCT00344318_exc_T53
Condition
seizures
NCT00344318_exc_T54
Observation
History
NCT00344318_exc_T55
Condition
febrile convulsion
NCT00344318_exc_T56
Qualifier
uncomplicated
NCT00344318_exc_T57
Multiplier
single
NCT00344318_exc_T59
Condition
neurological disease
NCT00344318_exc_T60
Condition
Acute disease
NCT00344318_exc_T61
Temporal
at the time of enrolment
NCT00344318_exc_T62
Condition
immunosuppressive condition
NCT00344318_exc_T63
Condition
immunodeficient condition
NCT00344318_exc_T64
Observation
family history
NCT00344318_exc_T65
Condition
congenital immunodeficiency
NCT00344318_exc_T66
Condition
hereditary immunodeficiency
NCT00344318_exc_T67
Scope
congenital or hereditary immunodeficiency
NCT00344318_exc_T68
Condition
Major congenital defects
NCT00344318_exc_T69
Condition
serious chronic illness
NCT00344318_exc_T70
Drug
immunoglobulins
NCT00344318_exc_T71
Drug
any blood products
NCT00344318_exc_T72
Temporal
since birth
NCT00344318_exc_T73
Scope
immunoglobulins and/or any blood products
NCT00344318_exc_T74
Observation
planned
NCT00344318_exc_T75
Temporal
during the active phase of the study
NCT00344318_exc_T76
Scope
since birth or planned administration during the active phase of the study
NCT00344318_exc_T77
Negation
with the exception of
NCT00344318_exc_T78
Reference_point
the first two weeks of life
NCT00344318_exc_T58
Negation
does not apply
NCT00344318_exc_T79
Scope
seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease
NCT00344318_exc_T80
Reference_point
enrolment
NCT00344318_exc_T81
Reference_point
active phase of the study
NCT00344318_exc_T82
Reference_point
birth
NCT00344318_exc_T83
Reference_point
each dose of vaccine(s)
NCT00344318_exc_T84
Reference_point
dose 1 and dose 2
NCT00344318_exc_T85
Reference_point
dose 3